Evidence map›Paper›PMID 39974629›Full record

ArticleACS pharmacology & translational science2025

Characterization of the Active Enantiomer and Mapping of the Stereospecific Intermolecular Pattern of a Reference P2X7 Allosteric Antagonist.

Andrew McGown, Nicolas Renault, Amélie Barczyk, Jordan Nafie, Luciano Barluzzi, Daniel Guest, Graham J Tizzard, Simon J Coles, David Leach, Daniel von Emloh and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Andrew McGownDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer BN1 9QJ, U.K.
Nicolas RenaultUniv. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille F-59000, France.
Amélie BarczykUniv. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille F-59000, France.
Jordan NafieBiotools, Inc., 17546 Beeline Highway, Jupiter, Florida 33458, United States.
Luciano BarluzziDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer BN1 9QJ, U.K.ORCID https://orcid.org/0000-0001-6682-342X
Daniel GuestDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer BN1 9QJ, U.K.
Graham J TizzardNational Crystallography Service, School of Chemistry, University of Southampton, Southampton SO17 1BJ, U.K.
Simon J ColesNational Crystallography Service, School of Chemistry, University of Southampton, Southampton SO17 1BJ, U.K.ORCID https://orcid.org/0000-0001-8414-9272
David LeachReach Separations Ltd, BioCity, Nottingham, Pennyfoot Street, Nottingham NG1 1GF, U.K.
Daniel von EmlohReach Separations Ltd, BioCity, Nottingham, Pennyfoot Street, Nottingham NG1 1GF, U.K.
Léa SuttonReach Separations Ltd, BioCity, Nottingham, Pennyfoot Street, Nottingham NG1 1GF, U.K.ORCID https://orcid.org/0009-0003-6883-9611
Kiera BaileyReach Separations Ltd, BioCity, Nottingham, Pennyfoot Street, Nottingham NG1 1GF, U.K.
Lewis EdmundsReach Separations Ltd, BioCity, Nottingham, Pennyfoot Street, Nottingham NG1 1GF, U.K.
Barnaby W GreenlandDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer BN1 9QJ, U.K.ORCID https://orcid.org/0000-0002-8416-4955
Régis MilletUniv. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille F-59000, France.
John SpencerDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer BN1 9QJ, U.K.ORCID https://orcid.org/0000-0001-5231-8836
Xavier DezitterUniv. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, Lille F-59000, France.ORCID https://orcid.org/0000-0001-6932-6947

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The P2X purinergic receptor 7 (P2X7) has an essential role in inflammation, innate immunity, tumor progression, neurodegenerative diseases, and several other diseases, leading subsequently to the development of P2X7 modulators. AZ11645373 is a frequently studied P2X7 antagonist tool compound but always used as a racemic mixture. Racemic AZ11645373 can be separated into its respective enantiomers by chiral chromatography, albeit in small batches, and these were stereochemically intact over two years later, by chiral high-performance liquid chromatography (HPLC) analysis. On a higher scale, significant decomposition is observed during purification. One of the enantiomers was crystallized as a palladium complex, and its (

Identifiers

PMID39974629
PMCPMC11833722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.